Literature DB >> 9854602

The phenotype of ostensibly healthy women who are carriers for ornithine transcarbamylase deficiency.

N E Maestri1, C Lord, M Glynn, A Bale, S W Brusilow.   

Abstract

Ornithine transcarbamylase (OTC) deficiency is an X-linked disorder of urea synthesis. Among females who carry a mutant OTC allele, there is a wide range of phenotypic variability, ranging from apparent normality to a severe onset and the resulting profound neurologic impairment observed in hemizygous males. This study was designed to define the phenotypic variability of OTC deficiency in ostensibly healthy carrier females and to compare them to noncarrier females from their own and other families. One hundred seventy-five women from 89 families participated in this study. Each completed a mailed questionnaire, allopurinol testing, and fasting plasma amino acid determinations. OTC carrier status was determined by pedigree analysis, allopurinol test results, and/or DNA mutation analysis. Overall, 79 women were identified as carriers of a mutant OTC allele (60 proband mothers, 19 relatives), and 96 women (32 proband mothers, 64 female relatives) were determined to be noncarriers. Comparison of biochemical phenotypes indicated that carriers and noncarriers do not differ in daily urinary creatinine excretion, but that carriers excrete significantly less urea nitrogen and total nitrogen, reflecting their significantly lower historically reported daily protein intake. Carriers had significantly higher levels of fasting plasma glutamine and alanine, and significantly lower levels of citrulline and arginine compared with noncarriers. Carriers and noncarriers reported similar demographic characteristics, anthropometric measurements, level of education, and medical and pregnancy histories. There was no indication of increased incidence of migraine headaches among carriers. Thus, we found no evidence that asymptomatic adult female OTC heterozygotes are at increased risk for previously unidentified health problems apart from an unknown risk for hyperammonemic encephalopathy as occurred in 3 of the carriers in this study. Because these episodes appear to be related to physiologic stress (fracture, parturition), it would seem medically prudent for carriers to be aware of this risk.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9854602

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  24 in total

1.  Fatal hyperammonemic coma caused by ornithine transcarbamylase deficiency in a woman.

Authors:  T Perpoint; L Argaud; Q Blanc; D Robert
Journal:  Intensive Care Med       Date:  2001-11-07       Impact factor: 17.440

2.  Biochemical data in ornithine transcarbamylase deficiency (OTCD) carrier risk estimation: logistic discrimination and combination with genetic information.

Authors:  Konrad Oexle
Journal:  J Hum Genet       Date:  2006-02-02       Impact factor: 3.172

3.  Hyperammonaemic encephalopathy induced by a commercial very-low-energy diet in a neglected ornithine-carbamoyltransferase-deficient woman.

Authors:  S Vinzio; A E Perrin; E Forestier; J L Schlienger; B Goichot
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

4.  Neurological outcome of patients with ornithine carbamoyltransferase deficiency.

Authors:  P Nicolaides; D Liebsch; N Dale; J Leonard; R Surtees
Journal:  Arch Dis Child       Date:  2002-01       Impact factor: 3.791

5.  Ornithine transcarbamylase deficiency with persistent abnormality in cerebral glutamate metabolism in adults.

Authors:  Andrea L Gropman; Napapon Sailasuta; Kent C Harris; Osama Abulseoud; Brian D Ross
Journal:  Radiology       Date:  2009-06-30       Impact factor: 11.105

6.  Diffusion tensor imaging detects areas of abnormal white matter microstructure in patients with partial ornithine transcarbamylase deficiency.

Authors:  A L Gropman; B Gertz; K Shattuck; I L Kahn; R Seltzer; L Krivitsky; J Van Meter
Journal:  AJNR Am J Neuroradiol       Date:  2010-05-20       Impact factor: 3.825

Review 7.  Genotype-Phenotype Correlations in Ornithine Transcarbamylase Deficiency: A Mutation Update.

Authors:  Ljubica Caldovic; Iman Abdikarim; Sahas Narain; Mendel Tuchman; Hiroki Morizono
Journal:  J Genet Genomics       Date:  2015-05-19       Impact factor: 4.275

Review 8.  Patterns of brain injury in inborn errors of metabolism.

Authors:  Andrea L Gropman
Journal:  Semin Pediatr Neurol       Date:  2012-12       Impact factor: 1.636

9.  AAV gene therapy corrects OTC deficiency and prevents liver fibrosis in aged OTC-knock out heterozygous mice.

Authors:  Lili Wang; Peter Bell; Hiroki Morizono; Zhenning He; Elena Pumbo; Hongwei Yu; John White; Mark L Batshaw; James M Wilson
Journal:  Mol Genet Metab       Date:  2017-03-02       Impact factor: 4.797

Review 10.  Dominant versus recessive: molecular mechanisms in metabolic disease.

Authors:  Johannes Zschocke
Journal:  J Inherit Metab Dis       Date:  2008-10-21       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.